{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:20:54Z","timestamp":1789158054724,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304978"],"award-info":[{"award-number":["82304978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174314"],"award-info":[{"award-number":["82174314"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3503501"],"award-info":[{"award-number":["2023YFC3503501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Primary membranous nephropathy (PMN) is one of the main causes of nephrotic syndrome in adults, with edema as the primary symptom. The Mafu Yishen Formula (MFYS) is derived from a combination of classical\u00a0prescriptions for treating edema diseases recorded in the\n                      <jats:italic>Treatise on Cold Damage and Miscellaneous Diseases<\/jats:italic>\n                      . While clinical efficacy of MFYS in treating PMN has been supported by evidence-based studies, its specific mechanisms remain unclear. This study aims to investigate the therapeutic effects and molecular mechanisms of MFYS in the treatment of membranous nephropathy, with a focus on whether MFYS promotes regulatory T cells (Treg) differentiation and modulates immune responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The passive Heymann nephritis (PHN) rat model was employed to simulate human PMN. Rats were treated with either low- or high-dose Mafu Yishen Formula (MFYS) or cyclosporine A (CsA) as a positive control. Urinary protein levels, serum biochemical parameters, renal pathological changes, and podocyte injury were evaluated. Immunofluorescence and flow cytometry were used to assess renal IgG deposition, B cell proliferation, and the proportion of Treg. Serum cytokine levels were measured using appropriate assays. The absorbed components of MFYS were identified via metabolomic analysis. Integrated strategies including network pharmacology, spleen transcriptomics, and proteomics were applied to identify key targets and signaling pathways. In vitro Treg polarization assays, supplemented with pathway inhibitors, were conducted to validate mechanistic findings. Molecular docking simulations were performed to explore interactions between active components of MFYS and potential target proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MFYS significantly reduced urinary protein levels in PHN rats, improved biochemical indicators such as serum albumin and blood lipids. Pathological examination revealed that MFYS alleviated glomerular and podocyte injury, while also reducing intrarenal IgG deposition and suppressing splenic B cell activation. Serum tests indicated that MFYS increased levels of IL-2 and IL-10 while decreasing levels of IL-6 and IL-17. Notably, MFYS significantly increased the proportion of Tregs. Integrated network pharmacology and multi-omics analysis consistently revealed that MFYS upregulates the PI3K\/AKT signaling pathway and enhances mitochondrial oxidative phosphorylation. Furthermore, MFYS intervention down regulated pSTAT3 expression while promoting PGC-1\u03b1 expression. In vitro experiments further confirmed that MFYS directly promotes the differentiation of na\u00efve T cells into Tregs, an effect that was counteracted by a PI3K\/AKT pathway inhibitor. Molecular docking results suggested that some active components of MFYS can bind to AKT1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MFYS modulates the immune response in PHN rats, reduces IgG deposition, and ameliorates renal and podocyte injury. It promotes Treg differentiation, regulates the cytokine network, and exerts multi-target effects on both inflammation and metabolism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01272-1","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:02:22Z","timestamp":1767664942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mafu Yishen Formula ameliorates membranous nephropathy by promotion of regulatory T cell differentiation: a multi-omics study"],"prefix":"10.1186","volume":"21","author":[{"given":"Qihan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"1","key":"1272_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1272_CR2","doi-asserted-by":"publisher","first-page":"2381614","DOI":"10.1080\/0886022X.2024.2381614","volume":"46","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang L, Yuan L, Xie Q, Liu S, Hao CM. Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China. Ren Fail. 2024;46(2):2381614. https:\/\/doi.org\/10.1080\/0886022X.2024.2381614.","journal-title":"Ren Fail"},{"issue":"Pt A","key":"1272_CR3","doi-asserted-by":"publisher","first-page":"109412","DOI":"10.1016\/j.intimp.2022.109412","volume":"113","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Dai H, Hu Y, Jiang H, Feng Z, Liu W, et al. Cytokines network in primary membranous nephropathy. Int Immunopharmacol. 2022;113(Pt A):109412.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1272_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","volume":"8","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera JE, Ortiz A, Fervenza FC. Novel treatments paradigms: membranous nephropathy. Kidney Int Rep. 2023;8(3):419\u201331.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"1272_CR5","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.ekir.2025.05.013","volume":"10","author":"MJ Vargas-Brochero","year":"2025","unstructured":"Vargas-Brochero MJ, Lafaut E, Radhakrishnan Y, Russo I, Sethi S, Zand L, et al. Long-term outcome of adult patients with membranous nephropathy treated with rituximab. Kidney Int Rep. 2025;10(8):2630\u201341.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"1272_CR6","doi-asserted-by":"publisher","first-page":"2320834","DOI":"10.1080\/0886022X.2024.2320834","volume":"46","author":"N Zhang","year":"2024","unstructured":"Zhang N, Jiang H, Dai H, Huang S, Zhao Q, Zhang N, et al. Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial. Ren Fail. 2024;46(1):2320834. https:\/\/doi.org\/10.1080\/0886022X.2024.2320834.","journal-title":"Ren Fail"},{"key":"1272_CR7","doi-asserted-by":"publisher","first-page":"116583","DOI":"10.1016\/j.biopha.2024.116583","volume":"174","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Dai H, Jiang H, Zhang N, Hou F, Zheng Y, et al. Activation of the IL-6\/STAT3 pathway contributes to the pathogenesis of membranous nephropathy and is a target for Mahuang Fuzi and Shenzhuo Decoction (MFSD) to repair podocyte damage. Biomed Pharmacother. 2024;174:116583.","journal-title":"Biomed Pharmacother"},{"key":"1272_CR8","doi-asserted-by":"publisher","first-page":"926368","DOI":"10.3389\/fimmu.2022.926368","volume":"13","author":"N Zhang","year":"2022","unstructured":"Zhang N, Dai H, Dong X, Liu W, Jiang H, Zhao Q, et al. Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time. Front Immunol. 2022;13:926368.","journal-title":"Front Immunol"},{"key":"1272_CR9","doi-asserted-by":"publisher","first-page":"155452","DOI":"10.1016\/j.cyto.2021.155452","volume":"141","author":"R Motavalli","year":"2021","unstructured":"Motavalli R, Etemadi J, Soltani-Zangbar MS, Ardalan MR, Kahroba H, Roshangar L, et al. Altered Th17\/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. Cytokine. 2021;141:155452. https:\/\/doi.org\/10.1016\/j.cyto.2021.155452.","journal-title":"Cytokine"},{"key":"1272_CR10","doi-asserted-by":"publisher","first-page":"665629","DOI":"10.3389\/fimmu.2021.665629","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Dai H, Liu X, Jiang H, Liu W, Feng Z, et al. Helper T cells in idiopathic membranous nephropathy. Front Immunol. 2021;12:665629. https:\/\/doi.org\/10.3389\/fimmu.2021.665629.","journal-title":"Front Immunol"},{"issue":"2","key":"1272_CR11","doi-asserted-by":"publisher","first-page":"103257","DOI":"10.1016\/j.autrev.2022.103257","volume":"22","author":"Y Li","year":"2023","unstructured":"Li Y, Liu H, Yan H, Xiong J. Research advances on targeted-Treg therapies on immune-mediated kidney diseases. Autoimmun Rev. 2023;22(2):103257.","journal-title":"Autoimmun Rev"},{"key":"1272_CR12","doi-asserted-by":"publisher","first-page":"112341","DOI":"10.1016\/j.exger.2023.112341","volume":"185","author":"X Tang","year":"2024","unstructured":"Tang X, Dai H, Hu Y, Liu W, Zhao Q, Jiang H, et al. Experimental models for elderly patients with membranous nephropathy: application and advancements. Exp Gerontol. 2024;185:112341.","journal-title":"Exp Gerontol"},{"issue":"9","key":"1272_CR13","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1681\/ASN.2021101384","volume":"33","author":"S Gao","year":"2022","unstructured":"Gao S, Cui Z, Zhao MH. Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy. J Am Soc Nephrol. 2022;33(9):1742\u201356.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1272_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/ni.2418","volume":"13","author":"DP Calado","year":"2012","unstructured":"Calado DP, Sasaki Y, Godinho SA, Pellerin A, Kochert K, Sleckman BP, et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol. 2012;13(11):1092\u2013100.","journal-title":"Nat Immunol"},{"key":"1272_CR15","doi-asserted-by":"publisher","first-page":"114607","DOI":"10.1016\/j.intimp.2025.114607","volume":"154","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Ruan X, Zhou X, Li S, Wang C, Huang L, et al. Phlorizin attenuates lupus nephritis via upregulating PI3K\/Akt pathway-mediated Treg differentiation. Int Immunopharmacol. 2025;154:114607. https:\/\/doi.org\/10.1016\/j.intimp.2025.114607.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1272_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","volume":"92","author":"M Rosenzwajg","year":"2017","unstructured":"Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int. 2017;92(1):227\u201337.","journal-title":"Kidney Int"},{"issue":"2","key":"1272_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","volume":"56","author":"S Dikiy","year":"2023","unstructured":"Dikiy S, Rudensky AY. Principles of regulatory T cell function. Immunity. 2023;56(2):240\u201355.","journal-title":"Immunity"},{"issue":"1","key":"1272_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10020-022-00574-6","volume":"28","author":"Q Xu","year":"2022","unstructured":"Xu Q, Zhang X, Li T, Shao S. Exenatide regulates Th17\/Treg balance via PI3K\/Akt\/FoxO1 pathway in db\/db mice. Mol Med. 2022;28(1):144.","journal-title":"Mol Med"},{"issue":"1","key":"1272_CR19","doi-asserted-by":"publisher","first-page":"2228420","DOI":"10.1080\/1547691X.2023.2228420","volume":"20","author":"H Li","year":"2023","unstructured":"Li H, Yu L, Ding Y, Nie Y, Yang M. Yin Yang 1 impacts upon preeclampsia by regulating T(reg)\/T(H)17 cells and PI3K\/AKT pathway. J Immunotoxicol. 2023;20(1):2228420. https:\/\/doi.org\/10.1080\/1547691X.2023.2228420.","journal-title":"J Immunotoxicol"},{"key":"1272_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MIR0817-349R","author":"SL Pompura","year":"2018","unstructured":"Pompura SL, Dominguez-Villar M. The PI3K\/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol. 2018. https:\/\/doi.org\/10.1002\/JLB.2MIR0817-349R.","journal-title":"J Leukoc Biol"},{"issue":"07","key":"1272_CR21","first-page":"1217","volume":"27","author":"Z Huang","year":"2025","unstructured":"Huang Z, Ma T, Wang C, et al. Exploration of targets and potential new efficacies of Qinzhi Zhudan Decoction in encephalopathy based on thermal proteome profiling. Mod Chin Med. 2025;27(07):1217\u201327.","journal-title":"Mod Chin Med"},{"issue":"5","key":"1272_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.leukres.2006.08.001","volume":"31","author":"T Ikezoe","year":"2007","unstructured":"Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, et al. Longitudinal inhibition of PI3K\/Akt\/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res. 2007;31(5):673\u201382.","journal-title":"Leuk Res"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01272-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:02:23Z","timestamp":1767664943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01272-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01272-1","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University (BJTCM-M-2024-09-05).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}